logo-loader
RNS
viewCello Health PLC

Cello Health PLC - Annual Report and Notice of AGM

RNS Number : 2601K
Cello Health PLC
21 April 2020
 

21 April 2020

Cello Health plc

("Cello" or the "Company")

 

 

Posting of Annual Report and Notice of AGM

 

Cello Health plc (AIM: CLL), the global healthcare-led advisory group, announces that it is today posting to shareholders its annual report and accounts for the year ended 31 December 2019 (the "2019 Accounts"), its notice of Annual General Meeting ("AGM") and an accompanying letter (the "Accompanying Letter").

As described in the Accompanying Letter, in the light of the COVID-19 pandemic and, in particular, following the announcement by the UK Prime Minister on 23 March 2020 prohibiting public gatherings, the Board has decided to move the venue for the AGM from Central London to the offices of Cello Health Consulting in Farnham, Surrey. Furthermore, as announced on 7 April 2020, the Board has decided that it is prudent to withdraw the recommendation to pay the final dividend of 2.95 pence per share. Consequently, the dividend resolution referred to in the notice of AGM included in the Annual Report will not now be put to the meeting.

The Company advises that, if the stay at home measures remain in place, the meeting will be a procedural meeting, and only the formal business set out in the revised notice of AGM set out at the end of the Accompanying Letter will be considered, and attendance will be limited to a bare quorum comprised of two Directors who are shareholders. The Company regrets these necessary steps but it is important to comply with the law and seek to slow the spread of COVID-19, as well as protect the health and safety of shareholders, employees and the community as a whole whilst seeking to maintain the efficient functioning of the Company.

In the light of these measures, shareholders will not be permitted to attend the AGM and the Directors of the Company strongly encourage shareholders to vote by proxy on all of the matters of business by appointing the Chairman of the Meeting as their proxy by submitting a proxy appointment in accordance with the instructions in the notice of meeting and the proxy form. The Company has made arrangements for shareholders holding their shares in certificated form to vote electronically. Questions to Directors can be sent to [email protected], and these will be answered in due course after the meeting.

Included in the Company's 2019 Accounts is a notice of AGM which sought to convene a meeting to be held in Central London and included a resolution to approve a final dividend. For the reasons noted above, the notice of AGM included in the 2019 Accounts has been replaced by the notice of AGM set out at the end of the Accompanying Letter, and the former AGM notice should therefore be disregarded.

Cello's 2020 AGM will be held at 12.30pm on Wednesday 20 May 2020 at the offices of Cello Health Consulting, Cello House, West Street, Farnham GU9 7EQ.

Copies of the notice of AGM, Accompanying Letter and 2019 Accounts are available to view on the Company's website, https://cellohealthplc.com.

 

 

Enquiries

Cello Health

020 7812 8460

Mark Scott, Chief Executive


Mark Bentley, Group Finance Director




Cenkos Securities

  020 7397 8900

Giles Balleny


Harry Hargreaves




Buchanan

  020 7466 5000

Mark Court


Jamie Hooper


Charlotte Slater


 

 

Notes to Editors

Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading scientific, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

Cello Health plc enables clients to commercialise, differentiate their assets, and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia, New Jersey, London, Edinburgh, and Farnham.

For further information, please visit: https://cellohealthplc.com

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCDZGZDVGFGGZM

Quick facts: Cello Health PLC

Price: 163

Market: AIM
Market Cap: £173.91 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Cello Group hails the impact of a “vibrant” US on the company’s performance

Chief executive of Cello Group (LON:CLL) Mark Scott spoke to Proactive’s Charlotte Kan in the wake of an upbeat trading update from healthcare and strategic consumer marketing specialist. The research and communications operations both performed well, but there was a common theme to update...

on 05/11/2016